JP2013533317A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013533317A5 JP2013533317A5 JP2013524194A JP2013524194A JP2013533317A5 JP 2013533317 A5 JP2013533317 A5 JP 2013533317A5 JP 2013524194 A JP2013524194 A JP 2013524194A JP 2013524194 A JP2013524194 A JP 2013524194A JP 2013533317 A5 JP2013533317 A5 JP 2013533317A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- unsubstituted
- independently selected
- hcv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 105
- 229910052739 hydrogen Inorganic materials 0.000 claims description 51
- 239000001257 hydrogen Substances 0.000 claims description 51
- 125000000623 heterocyclic group Chemical group 0.000 claims description 36
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 34
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 34
- 125000003118 aryl group Chemical group 0.000 claims description 28
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 28
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 27
- 150000002431 hydrogen Chemical class 0.000 claims description 24
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 claims description 21
- 229910052760 oxygen Inorganic materials 0.000 claims description 20
- 125000005843 halogen group Chemical group 0.000 claims description 19
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 15
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 claims description 15
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 15
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims description 15
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 14
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 14
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 14
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 229910052717 sulfur Inorganic materials 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 125000004702 alkoxy alkyl carbonyl group Chemical group 0.000 claims description 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 8
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 8
- 125000001188 haloalkyl group Chemical group 0.000 claims description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 claims description 7
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 7
- 125000005170 cycloalkyloxycarbonyl group Chemical group 0.000 claims description 7
- 125000005144 cycloalkylsulfonyl group Chemical group 0.000 claims description 7
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 7
- 125000004993 haloalkoxycarbonyl group Chemical group 0.000 claims description 7
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 7
- 125000005182 hydroxyalkylcarbonyl group Chemical group 0.000 claims description 7
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 150000001721 carbon Chemical group 0.000 claims description 6
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 6
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims description 6
- 239000001301 oxygen Chemical group 0.000 claims description 6
- 125000003003 spiro group Chemical group 0.000 claims description 6
- 239000011593 sulfur Chemical group 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 108010050904 Interferons Proteins 0.000 claims 8
- 102000014150 Interferons Human genes 0.000 claims 8
- 229940079322 interferon Drugs 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 208000015181 infectious disease Diseases 0.000 claims 4
- 101710200424 Inosine-5'-monophosphate dehydrogenase Proteins 0.000 claims 2
- 102100040018 Interferon alpha-2 Human genes 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 2
- 102000005741 Metalloproteases Human genes 0.000 claims 2
- 108010006035 Metalloproteases Proteins 0.000 claims 2
- 108060004795 Methyltransferase Proteins 0.000 claims 2
- 101800001019 Non-structural protein 4B Proteins 0.000 claims 2
- 101800001014 Non-structural protein 5A Proteins 0.000 claims 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 2
- 102000012479 Serine Proteases Human genes 0.000 claims 2
- 108010022999 Serine Proteases Proteins 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229960000329 ribavirin Drugs 0.000 claims 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 0 *C(*C(*1)=CN=C1C1N(*)C*C1)=*1*CCCCCC1 Chemical compound *C(*C(*1)=CN=C1C1N(*)C*C1)=*1*CCCCCC1 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37307010P | 2010-08-12 | 2010-08-12 | |
| US61/373,070 | 2010-08-12 | ||
| US13/198,529 US20120195857A1 (en) | 2010-08-12 | 2011-08-04 | Hepatitis C Virus Inhibitors |
| US13/198,529 | 2011-08-04 | ||
| PCT/US2011/047211 WO2012021591A1 (en) | 2010-08-12 | 2011-08-10 | Hepatitis c virus inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013533317A JP2013533317A (ja) | 2013-08-22 |
| JP2013533317A5 true JP2013533317A5 (https=) | 2014-09-11 |
| JP5805763B2 JP5805763B2 (ja) | 2015-11-04 |
Family
ID=44534668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013524194A Expired - Fee Related JP5805763B2 (ja) | 2010-08-12 | 2011-08-10 | Ｃ型肝炎ウイルス阻害剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20120195857A1 (https=) |
| EP (1) | EP2603504A1 (https=) |
| JP (1) | JP5805763B2 (https=) |
| CN (1) | CN103249731A (https=) |
| AR (1) | AR082681A1 (https=) |
| BR (1) | BR112013003101A2 (https=) |
| CA (1) | CA2808061A1 (https=) |
| EA (1) | EA024171B1 (https=) |
| MX (1) | MX2013001579A (https=) |
| TW (1) | TW201211032A (https=) |
| WO (1) | WO2012021591A1 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8303944B2 (en) | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| IN2012DN00999A (https=) | 2009-07-16 | 2015-04-10 | Vertex Pharma | |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2794145A1 (en) | 2010-03-24 | 2011-09-29 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
| BR112013004520A2 (pt) | 2010-08-26 | 2016-06-07 | Univ Emory | inibidores potentes e seletivos do virus da hepatite c |
| EP2651928A4 (en) * | 2010-12-15 | 2014-06-18 | Abbvie Inc | ANTI-VIRAL COMPOUNDS |
| US8552047B2 (en) * | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| BR112013022552B1 (pt) | 2011-03-04 | 2021-11-23 | Newgen Therapeutics, Inc | Compostos de quinazolina substituídos com alcino, seu uso, composição farmacêutica, e kit |
| US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2012155339A1 (zh) | 2011-05-17 | 2012-11-22 | 江苏康缘药业股份有限公司 | 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途 |
| US9303061B2 (en) | 2011-07-09 | 2016-04-05 | Sunshine Luke Pharma Co., Ltd. | Spiro compounds as Hepatitis C virus inhibitors |
| WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
| CN103946220B (zh) | 2011-11-03 | 2017-12-22 | 施万生物制药研发Ip有限责任公司 | 含有片段{2‑[4‑(联苯‑4‑基)‑1h‑咪唑‑2‑基]吡咯烷‑1‑羰基甲基}胺的杆状丙型肝炎病毒抑制剂 |
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2862755A1 (en) | 2012-02-10 | 2013-08-15 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
| HUE032173T2 (en) | 2012-04-25 | 2017-09-28 | Theravance Biopharma R&D Ip Llc | Piperazine piperidine compounds as inhibitors of hepatitis C virus |
| MX2014013489A (es) * | 2012-05-09 | 2015-02-12 | Bayer Cropscience Ag | 5-halogenopirazolindanil carboxamidas. |
| CN103420991B (zh) * | 2012-05-17 | 2017-07-07 | 乳源东阳光药业有限公司 | 作为丙型肝炎抑制剂的吡咯烷衍生物及其在药物中的应用 |
| TWI610916B (zh) | 2012-08-03 | 2018-01-11 | 廣東東陽光藥業有限公司 | 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用 |
| TW201412709A (zh) * | 2012-09-28 | 2014-04-01 | Sunshine Lake Pharma Co Ltd | 作為丙型肝炎抑制劑的螺環化合物及其在藥物中的應用 |
| US9802949B2 (en) | 2012-11-29 | 2017-10-31 | Sunshine Lake Pharma Co., Ltd. | Fused ring compounds as hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof |
| CN103848819B (zh) * | 2012-11-29 | 2017-04-12 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的螺环化合物、药物组合物及它们在药物中的应用 |
| US9416139B2 (en) | 2012-11-29 | 2016-08-16 | Sunshine Lake Pharma Co., Ltd. | Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| US9775831B2 (en) | 2013-07-17 | 2017-10-03 | Bristol-Myers Squibb Company | Combinations comprising biphenyl derivatives for use in the treatment of HCV |
| JP6306874B2 (ja) * | 2013-12-20 | 2018-04-04 | 住友化学株式会社 | 臭素化合物の製造方法 |
| CN104803989B (zh) * | 2014-01-23 | 2017-12-22 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的桥环化合物及其在药物中的应用 |
| CN105085493A (zh) * | 2014-04-15 | 2015-11-25 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的螺环化合物及其在药物中的应用 |
| CN105272972B (zh) * | 2014-05-30 | 2018-12-11 | 上海唐润医药科技有限公司 | 具有抗病毒活性的苯并杂环己二烯衍生物 |
| WO2015184644A1 (zh) * | 2014-06-06 | 2015-12-10 | 爱博新药研发(上海)有限公司 | 抑制丙肝病毒的化合物、药物组合物及其应用 |
| NZ726343A (en) * | 2014-06-12 | 2018-04-27 | Gilead Sciences Inc | Antiviral compounds |
| TWI675029B (zh) * | 2014-12-16 | 2019-10-21 | 大陸商廣東東陽光藥業有限公司 | 作為丙型肝炎抑制劑的橋環化合物及其製備方法 |
| US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2017076201A1 (zh) * | 2015-11-06 | 2017-05-11 | 江苏豪森药业集团有限公司 | Hcv抑制剂、其制备方法与应用 |
| ES2881776T3 (es) | 2016-03-08 | 2021-11-30 | Novartis Ag | Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus |
| JOP20170169A1 (ar) | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
| KR20230031990A (ko) | 2018-02-28 | 2023-03-07 | 노파르티스 아게 | 인플루엔자의 치료를 위한 오르토믹소바이러스 복제의 억제제로서의 10-(디(페닐)메틸)-4-히드록시-8,9,9a,10-테트라히드로-7h-피롤로[1',2':4,5]피라지노[1,2-b]피리다진-3,5-디온 유도체 및 관련 화합물 |
| WO2020112357A1 (en) * | 2018-11-28 | 2020-06-04 | The Regents Of The University Of Michigan | Succinate dehydrogenase inhibitors and methods of making and using the same |
| JP2025525344A (ja) | 2022-06-21 | 2025-08-05 | アストラゼネカ・アクチエボラーグ | Ｎ－（２－（４－シアノチアゾリジン－３－イル）－２－オキソエチル）－キノリン－４－カルボキサミド |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004014852A2 (en) | 2002-08-12 | 2004-02-19 | Bristol-Myers Squibb Company | Iminothiazolidinones as inhibitors of hcv replication |
| DE102004036971B4 (de) | 2004-07-30 | 2009-07-30 | Advanced Micro Devices, Inc., Sunnyvale | Technik zur Bewertung lokaler elektrischer Eigenschaften in Halbleiterbauelementen |
| WO2006093867A1 (en) | 2005-02-28 | 2006-09-08 | The Rockefeller University | Structure of the hepatitits c virus ns5a protein |
| US7659270B2 (en) * | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7728027B2 (en) * | 2007-08-08 | 2010-06-01 | Bristol-Myers Squibb Company | Process for synthesizing compounds useful for treating hepatitis C |
| ATE551337T1 (de) * | 2008-02-12 | 2012-04-15 | Bristol Myers Squibb Co | Inhibitoren des hepatitis-c-virus |
| US8147818B2 (en) | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| SI2373172T1 (sl) * | 2008-12-03 | 2013-12-31 | Presidio Pharmaceuticals, Inc. | Inhibitorji HCV NS5A |
| PT3309157T (pt) * | 2009-05-13 | 2019-12-02 | Gilead Pharmasset Llc | Compostos antivirais |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| CN104530079B (zh) * | 2009-12-18 | 2017-10-20 | 北京凯因科技股份有限公司 | C型肝炎病毒复制的新型抑制剂 |
-
2011
- 2011-08-04 US US13/198,529 patent/US20120195857A1/en not_active Abandoned
- 2011-08-10 WO PCT/US2011/047211 patent/WO2012021591A1/en not_active Ceased
- 2011-08-10 JP JP2013524194A patent/JP5805763B2/ja not_active Expired - Fee Related
- 2011-08-10 CN CN2011800457257A patent/CN103249731A/zh active Pending
- 2011-08-10 MX MX2013001579A patent/MX2013001579A/es not_active Application Discontinuation
- 2011-08-10 EA EA201390190A patent/EA024171B1/ru not_active IP Right Cessation
- 2011-08-10 EP EP11750005.8A patent/EP2603504A1/en not_active Withdrawn
- 2011-08-10 CA CA2808061A patent/CA2808061A1/en not_active Abandoned
- 2011-08-10 BR BR112013003101A patent/BR112013003101A2/pt not_active IP Right Cessation
- 2011-08-12 TW TW100128974A patent/TW201211032A/zh unknown
- 2011-08-12 AR ARP110102949A patent/AR082681A1/es unknown